Notably, the SOS study showed that in people with T2D, achieving and maintaining 15% WL over 15 years was associated with reductions in both micro- and macrovascular complications following BS [54]
2: 37 Peluso G, Barbarisi A, Savica V, et al
In clinical research, tesamorelin has been most consistently associated with reductions in visceral adipose tissue and favorable shifts in certain cardiometabolic markers , while ongoing investigation continues to explore its relevance in metabolic dysfunction and age-related changes in GH/IGF-1 dynamics
02 Body Weight & Adipose Research Phase 2 clinical data demonstrated significant reductions in total body weight, with research ongoing into the compound's effects on visceral fat, hepatic lipid accumulation, and lean mass preservation
Several variables influence your timeline
J.KarthikaR.RosanaO